Provided by Tiger Trade Technology Pte. Ltd.

Zenas BioPharma Inc.

21.82
+0.06000.28%
Post-market: 21.820.00000.00%17:18 EDT
Volume:316.96K
Turnover:6.88M
Market Cap:1.36B
PE:-2.59
High:22.01
Open:21.99
Low:21.27
Close:21.76
52wk High:44.60
52wk Low:8.51
Shares:62.37M
Float Shares:39.84M
Volume Ratio:0.64
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.4400
EPS(LYR):-8.4448
ROE:-136.22%
ROA:-35.06%
PB:5.62
PE(LYR):-2.58

Loading ...

Zenas BioPharma grants 41,475 inducement RSUs to new hires under 2026 plan

Reuters
·
Yesterday

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Yesterday

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Yesterday

Morgan Stanley Reaffirms Their Hold Rating on Zenas BioPharma, Inc. (ZBIO)

TIPRANKS
·
Apr 08

Zenas Biopharma director Hongbo Lu acquires ZBIO common shares worth $0.1 million

Reuters
·
Apr 03

Major Insider Move Signals Growing Confidence in Zenas BioPharma’s Future

TIPRANKS
·
Apr 02

Fairmount Healthcare Fund II acquires Zenas BioPharma shares worth $3 million

Reuters
·
Apr 02

Zenas BioPharma Raises Capital via Notes and Equity Offering

TIPRANKS
·
Apr 01

Zenas BioPharma director buys $1.5M in common stock

TIPRANKS
·
Apr 01

Zenas BioPharma director Hongbo Lu reports $1.5 million common share acquisition

Reuters
·
Apr 01

Top Midday Decliners

MT Newswires Live
·
Mar 28

Zenas BioPharma Tumble on Pricing of Convertible-Note, Stock Public Offerings

Dow Jones
·
Mar 28

BUZZ-U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services

Reuters
·
Mar 27

Zenas Biopharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock With Aggregate Gross Proceeds of $300.0 Million

THOMSON REUTERS
·
Mar 27

Stocks to Watch: Datacentrex, Unity Software, Veritone, Zenas BioPharma

Dow Jones
·
Mar 27

BUZZ-Zenas BioPharma drops on convertible, equity offerings

Reuters
·
Mar 27

Zenas Biopharma announces underwritten public offering of convertible senior notes due 2032; terms are set at pricing

Reuters
·
Mar 27

Zenas Biopharma Inc - Proceeds to Support Obexelimab U.S. Launch, Pipeline Advancement, and General Corporate Purposes

THOMSON REUTERS
·
Mar 27

Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

GlobeNewswire
·
Mar 27

Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis

TIPRANKS
·
Mar 21